Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

By M. Dudley, J. Wunderlich, P. Robbins, Jie Yang, P. Hwu, D. Schwartzentruber, S. Topalian, R. Sherry, N. Restifo, Amy M. Hubicki and 9 more. Science, 2002

3,012 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics

View Paper: https://www.semanticscholar.org/paper/8bc307f9e2c0736c36bd484a57c697fc992dcc53

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. W. Zou

In Genetics

1. S. Rosenberg
2. N. Restifo
3. T. Gajewski
4. M. Dudley
5. W. Zou
6. A. Mellor
7. Mauro Delorenzi
8. D. Munn

Citations in the corpus

• Mixed immunotherapy and chemotherapy of tumors: modeling, applications and biological interpretations. (2006, neutral): “NK and T cells are components of the process of stimulation and elimination of activated effector cells, a model simplification meant to reflect the self-regulatory nature of the immune system (see, e.g., Dudley et al., 2002; Germain, 2004; Jiang and Chess, 2004).”
• Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells (2003, background): “Our observations in the pmel-1 model, and in human patients treated with T cells ( 45 ), are that CD8� T cell activation results in the destruction of tumor cells at least as well as normal cells.”
• Adoptive-cell-transfer therapy for the treatment of patients with cancer (2003, background): “In practice, this strategy has led to substantial tumour regressions in patients with melanoma or lymphom”
• Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts (2010, background): “Adoptive transfer of high numbers of tumor-reactive lymphocytes into lymphoablated patients is a promising therapy for late metastatic disease, particularly metastatic melanoma (Dudley et al., 2002, 2008).”
• Cancer immunotherapy comes of age (2011, neutral): “The discovery that host lymphodepletion facilitates engraftment of adoptively transferred T cells has enabled the successful transfer of ex-vivo -expanded tumour-infiltrating lymphocytes (TILs) from patients with melanoma, with marked clinical responses, some of which are complete and durabl”
• CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells (2005, background): “One currently used and approved immunotherapeutic approach in humans involves lymphodepletion before adoptive transfer (58).”
• Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. (2008, background): “The persistence and antitumor efficacy of cultured T cells used for therapy of cancer can sometimes be improved by depletion of host lymphocytes before cell transfer to eliminate regulatory cells and competition for cytokines and by the administration of IL-2 after cell transfer (6, 17).”
• PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. (2014, neutral): “Adoptive transfer of ex vivo–expanded tumor-infiltrating lymphocytes (TILs) can cause substantial regression of metastatic melanoma (1, 2).”
• Novel cancer immunotherapy agents with survival benefit: recent successes and next steps (2011, background): “Other immunotherapy strategies, including ACT whereby T cells are administered to patient”